Review



pard3 (df3368)  (Affinity Biosciences)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Affinity Biosciences pard3 (df3368)
    Association of LKB1 with SIK1−3 and <t>PARD3</t> and their roles in GC. ( A ) The gene association network of LKB1 , SIK1 − 3 , and PARD3 was constructed using the GeneMANIA data portal. ( B ) Relationship between SIK2 expression and the survival curve of GC patients. ( C ) Relationship between SIK3 expression and the survival curve of GC patients. ( D ) The relationship between PARD3 and the survival curve of GC patients. ( E ) IHC staining of SIK2, SIK3, and PARD3 in paracancerous and GC tissues of GC patients (400×). ( F , G ) Differences in gene and protein expression levels of SIK2 , SIK3 , and PARD3 in paracancerous and GC tissues of GC patients ( n = 3). ( H , I ) Differential protein expression of LKB1, SIKs, and PARD3 in four GC cell lines and GES-1. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the normal group ( F ) or GES-1 group ( I ).
    Pard3 (Df3368), supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pard3+%28df3368%29/pmc11277420-227-20-27?v=Affinity+Biosciences
    Average 90 stars, based on 1 article reviews
    pard3 (df3368) - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway"

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms25147973

    Association of LKB1 with SIK1−3 and PARD3 and their roles in GC. ( A ) The gene association network of LKB1 , SIK1 − 3 , and PARD3 was constructed using the GeneMANIA data portal. ( B ) Relationship between SIK2 expression and the survival curve of GC patients. ( C ) Relationship between SIK3 expression and the survival curve of GC patients. ( D ) The relationship between PARD3 and the survival curve of GC patients. ( E ) IHC staining of SIK2, SIK3, and PARD3 in paracancerous and GC tissues of GC patients (400×). ( F , G ) Differences in gene and protein expression levels of SIK2 , SIK3 , and PARD3 in paracancerous and GC tissues of GC patients ( n = 3). ( H , I ) Differential protein expression of LKB1, SIKs, and PARD3 in four GC cell lines and GES-1. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the normal group ( F ) or GES-1 group ( I ).
    Figure Legend Snippet: Association of LKB1 with SIK1−3 and PARD3 and their roles in GC. ( A ) The gene association network of LKB1 , SIK1 − 3 , and PARD3 was constructed using the GeneMANIA data portal. ( B ) Relationship between SIK2 expression and the survival curve of GC patients. ( C ) Relationship between SIK3 expression and the survival curve of GC patients. ( D ) The relationship between PARD3 and the survival curve of GC patients. ( E ) IHC staining of SIK2, SIK3, and PARD3 in paracancerous and GC tissues of GC patients (400×). ( F , G ) Differences in gene and protein expression levels of SIK2 , SIK3 , and PARD3 in paracancerous and GC tissues of GC patients ( n = 3). ( H , I ) Differential protein expression of LKB1, SIKs, and PARD3 in four GC cell lines and GES-1. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the normal group ( F ) or GES-1 group ( I ).

    Techniques Used: Construct, Expressing, Immunohistochemistry

    Erianin inhibits the expression of LKB1, SIK2/3 and PARD3, but not SIK1, in GC cells. ( A ) Molecular docking conformation of Erianin and LKB1 (PDB ID: 2WTK). Arrows indicated the locations of LKB1 and Erianin. The black box magnifies the 3D view of the docking cavity of Erianin and LKB1. ( B , C ) Distribution of amino acid residues around the binding pocket of Erianin and LKB1 and the chemical bonds formed. The oxygen atom on Erianin formed hydrogen bonds with Ser148, Ser199, Ser154, Thr147, Met150 and Thr98. The oxygen atom on Erianin formed a weak hydrogen bond with Ser199, and the carbon atom formed a weak hydrogen bond with Asp157. The carbon atom on the benzene ring of Erianin formed hydrophobic interactions with Leu202 and Ile75. The carbon atom on the C=C connecting the two benzene rings in Erianin formed a hydrophobic interaction with Phe415. ( D , E ) Erianin inhibited the fluorescence intensity of LKB1 in MGC803 and MKN45 cells (scale bar = 50 μm). ( F ) Effects of treating MGC803 cells with an Erianin concentration gradient on the expression of LKB1 , SIK1 − 3 , and PARD3 genes. ( G , H ) Effects of treating MGC803 cells with an Erianin concentration gradient on the expression of LKB1, SIK1−3, and PARD3 proteins. ( I ) Effects of treating MKN45 cells with an Erianin concentration gradient on the expression of LKB1 , SIK1 − 3 , and PARD3 genes. ( J , K ) Effects of treating MKN45 cells with an Erianin concentration gradient on the protein expression of LKB1, SIK1−3, and PARD3. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the control group.
    Figure Legend Snippet: Erianin inhibits the expression of LKB1, SIK2/3 and PARD3, but not SIK1, in GC cells. ( A ) Molecular docking conformation of Erianin and LKB1 (PDB ID: 2WTK). Arrows indicated the locations of LKB1 and Erianin. The black box magnifies the 3D view of the docking cavity of Erianin and LKB1. ( B , C ) Distribution of amino acid residues around the binding pocket of Erianin and LKB1 and the chemical bonds formed. The oxygen atom on Erianin formed hydrogen bonds with Ser148, Ser199, Ser154, Thr147, Met150 and Thr98. The oxygen atom on Erianin formed a weak hydrogen bond with Ser199, and the carbon atom formed a weak hydrogen bond with Asp157. The carbon atom on the benzene ring of Erianin formed hydrophobic interactions with Leu202 and Ile75. The carbon atom on the C=C connecting the two benzene rings in Erianin formed a hydrophobic interaction with Phe415. ( D , E ) Erianin inhibited the fluorescence intensity of LKB1 in MGC803 and MKN45 cells (scale bar = 50 μm). ( F ) Effects of treating MGC803 cells with an Erianin concentration gradient on the expression of LKB1 , SIK1 − 3 , and PARD3 genes. ( G , H ) Effects of treating MGC803 cells with an Erianin concentration gradient on the expression of LKB1, SIK1−3, and PARD3 proteins. ( I ) Effects of treating MKN45 cells with an Erianin concentration gradient on the expression of LKB1 , SIK1 − 3 , and PARD3 genes. ( J , K ) Effects of treating MKN45 cells with an Erianin concentration gradient on the protein expression of LKB1, SIK1−3, and PARD3. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the control group.

    Techniques Used: Expressing, Binding Assay, Fluorescence, Concentration Assay, Control

    Silencing the expression of LKB1, SIKs, and PARD3 and their interaction. ( A , B ) Effects of silencing LKB1 expression on the expression of SIK1−3 and PARD3 in GC cells. ( C , D ) Effects of silencing SIK2 expression on the expression of LKB1 and PARD3 in GC cells. ( E , F ) Effects of silencing SIK3 expression on the expression of LKB1 and PARD3 in GC cells. ( G , H ) Effects of silencing PARD3 expression on the expression of LKB1 and SIK1−3 in GC cells. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the NC group.
    Figure Legend Snippet: Silencing the expression of LKB1, SIKs, and PARD3 and their interaction. ( A , B ) Effects of silencing LKB1 expression on the expression of SIK1−3 and PARD3 in GC cells. ( C , D ) Effects of silencing SIK2 expression on the expression of LKB1 and PARD3 in GC cells. ( E , F ) Effects of silencing SIK3 expression on the expression of LKB1 and PARD3 in GC cells. ( G , H ) Effects of silencing PARD3 expression on the expression of LKB1 and SIK1−3 in GC cells. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the NC group.

    Techniques Used: Expressing

    Erianin inhibits tumor growth and the expression of LKB1, SIK2, SIK3, and PARD3 in the CDX mouse model. ( A ) Schematic diagram of the CDX model construction and drug administration treatment strategy. ( B ) Axillary tumor growth of mice in the five groups. ( C ) The size of isolated tumors from mice in the five groups. ( D ) Body weight changes of mice in the five groups during the administration period. ( E ) Changes in tumor volume during the administration of mice in the five groups. ( F ) Tumor mass in the five groups of mice. ( G ) Liver, spleen, and kidney index of mice in each group. ( H ) Differences in liver MDA and SOD levels of mice in the five groups. ( I ) Representative photomicrographs of pathological staining of tumors, liver, spleen, and kidney tissues of mice in the five groups (200×). ( J ) IHC staining results of LKB1, SIK2, SIK3, and PARD3 in mouse tumor tissues in the five groups (400×). ( K ) Changes in protein expression of LKB1, SIK2, SIK3, and PARD3 in tumor tissues of mice in the five groups. ( L ) Changes in the expression of EMT marker proteins in tumor tissues of mice in the five groups. ** p < 0.01 indicates statistical difference compared to the vehicle control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the 5-FU 50 mg/kg group.
    Figure Legend Snippet: Erianin inhibits tumor growth and the expression of LKB1, SIK2, SIK3, and PARD3 in the CDX mouse model. ( A ) Schematic diagram of the CDX model construction and drug administration treatment strategy. ( B ) Axillary tumor growth of mice in the five groups. ( C ) The size of isolated tumors from mice in the five groups. ( D ) Body weight changes of mice in the five groups during the administration period. ( E ) Changes in tumor volume during the administration of mice in the five groups. ( F ) Tumor mass in the five groups of mice. ( G ) Liver, spleen, and kidney index of mice in each group. ( H ) Differences in liver MDA and SOD levels of mice in the five groups. ( I ) Representative photomicrographs of pathological staining of tumors, liver, spleen, and kidney tissues of mice in the five groups (200×). ( J ) IHC staining results of LKB1, SIK2, SIK3, and PARD3 in mouse tumor tissues in the five groups (400×). ( K ) Changes in protein expression of LKB1, SIK2, SIK3, and PARD3 in tumor tissues of mice in the five groups. ( L ) Changes in the expression of EMT marker proteins in tumor tissues of mice in the five groups. ** p < 0.01 indicates statistical difference compared to the vehicle control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the 5-FU 50 mg/kg group.

    Techniques Used: Expressing, Isolation, Staining, Immunohistochemistry, Marker, Control

    5-FU inhibits the expression of LKB1, SIK2, SIK3, and PARD3 in GC cells. ( A ) CCK8 assay showing the inhibitory effect of different concentrations of 5-FU on MGC803 cells. ( B ) CCK8 detected the inhibitory effect of different concentrations of 5-FU on MKN45 cells. ( C , D ) 5-FU inhibited the protein expression of LKB1, SIK2, SIK3 and PARD3 in MGC803 cells in a dose-dependent manner. ( E , F ) 5-FU inhibited the proteins expression of LKB1, SIK2, SIK3 and PARD3 in MKN45 cells in a dose-dependent manner. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the control group.
    Figure Legend Snippet: 5-FU inhibits the expression of LKB1, SIK2, SIK3, and PARD3 in GC cells. ( A ) CCK8 assay showing the inhibitory effect of different concentrations of 5-FU on MGC803 cells. ( B ) CCK8 detected the inhibitory effect of different concentrations of 5-FU on MKN45 cells. ( C , D ) 5-FU inhibited the protein expression of LKB1, SIK2, SIK3 and PARD3 in MGC803 cells in a dose-dependent manner. ( E , F ) 5-FU inhibited the proteins expression of LKB1, SIK2, SIK3 and PARD3 in MKN45 cells in a dose-dependent manner. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the control group.

    Techniques Used: Expressing, CCK-8 Assay, Control

    5−FU combined with Erianin inhibits the expression of LKB1, SIK2/3, and PARD3 in GC cells and the migration and invasion ability of cells. ( A ) CCK8 examined the inhibitory effect of Erianin 25 nM or Erianin 50 nM combined with different concentrations of 5-FU on the cell viability of MGC803 or MKN45 cells. ( B ) Inhibitory effects of Erianin at 25 nM combined with 2.5 μg/mL 5-FU, and Erianin at 50 nM combined with 2.5 μg/mL 5-FU on the cell viability of MGC803 or MKN45. ( C ) Erianin at 25 nM combined with 5-FU at 2.5 μg/mL inhibited the fluorescent expression of LKB1 in MGC803 cells (scale bar = 50 μm). ( D ) 50 nM Erianin combined with 2.5 μg/mL 5-FU inhibited the fluorescent expression of LKB1 in MKN45 cells (scale bar = 50 μm). ( E ) Erianin combined with 5-FU inhibited the protein expression of LKB1, SIK1−3, and PARD3 in MGC803 cells. ( F ) Erianin combined with 5-FU inhibited the protein expression of LKB1, SIK1−3, and PARD3 in MKN45 cells. ( G ) Erianin combined with 5-FU inhibited the migration and invasion of MGC803 cells (scale bar = 100 μm). ( H ) Erianin combined with 5-FU inhibited the migration and invasion of MKN45 cells (scale bar =100 μm). ( I ) Erianin combined with 5-FU inhibited wound healing of MGC803 cells (scale bar = 100 μm). ( J ) Erianin combined with 5-FU inhibited wound healing of MKN45 cells (scale bar = 200 μm). * p < 0.05, ** p <0.01 indicates statistical difference compared to the control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the Erianin+5FU group.
    Figure Legend Snippet: 5−FU combined with Erianin inhibits the expression of LKB1, SIK2/3, and PARD3 in GC cells and the migration and invasion ability of cells. ( A ) CCK8 examined the inhibitory effect of Erianin 25 nM or Erianin 50 nM combined with different concentrations of 5-FU on the cell viability of MGC803 or MKN45 cells. ( B ) Inhibitory effects of Erianin at 25 nM combined with 2.5 μg/mL 5-FU, and Erianin at 50 nM combined with 2.5 μg/mL 5-FU on the cell viability of MGC803 or MKN45. ( C ) Erianin at 25 nM combined with 5-FU at 2.5 μg/mL inhibited the fluorescent expression of LKB1 in MGC803 cells (scale bar = 50 μm). ( D ) 50 nM Erianin combined with 2.5 μg/mL 5-FU inhibited the fluorescent expression of LKB1 in MKN45 cells (scale bar = 50 μm). ( E ) Erianin combined with 5-FU inhibited the protein expression of LKB1, SIK1−3, and PARD3 in MGC803 cells. ( F ) Erianin combined with 5-FU inhibited the protein expression of LKB1, SIK1−3, and PARD3 in MKN45 cells. ( G ) Erianin combined with 5-FU inhibited the migration and invasion of MGC803 cells (scale bar = 100 μm). ( H ) Erianin combined with 5-FU inhibited the migration and invasion of MKN45 cells (scale bar =100 μm). ( I ) Erianin combined with 5-FU inhibited wound healing of MGC803 cells (scale bar = 100 μm). ( J ) Erianin combined with 5-FU inhibited wound healing of MKN45 cells (scale bar = 200 μm). * p < 0.05, ** p <0.01 indicates statistical difference compared to the control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the Erianin+5FU group.

    Techniques Used: Expressing, Migration, Control

    Erianin combined with 5-FU inhibits tumor growth in CDX mouse model. ( A ) Schematic diagram of the CDX mouse model construction and the administration strategy for Erianin combined with 5-FU. ( B ) Growth of subcutaneous tumors in mice. ( C ) Photographs of subcutaneous tumors in mice. ( D ) Body weight change curve of mice in each group during the administration period. ( E ) Tumor volume change curves of mice in the four groups during the administration period. ( F ) Tumor weight of mice in the four groups. ( G ) Liver, spleen, and kidney indices of mice in the four groups. ( H ) Differences in liver MDA and SOD contents among the four groups of mice. ( I ) H&E staining of tumors, liver, spleen, and kidneys of mice in the four groups (200×). ( J ) IHC staining of LKB1, SIK2, SIK3, and PARD3 in tumor tissues from mice in the four groups (400×). ( K ) Protein expression of LKB1, SIK2, SIK3, and PARD3 in tumor tissues from mice in the four groups. ( L ) Expression of EMT marker proteins in tumor tissues from mice in the four groups. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the Vehicle control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the Erianin+5-FU group.
    Figure Legend Snippet: Erianin combined with 5-FU inhibits tumor growth in CDX mouse model. ( A ) Schematic diagram of the CDX mouse model construction and the administration strategy for Erianin combined with 5-FU. ( B ) Growth of subcutaneous tumors in mice. ( C ) Photographs of subcutaneous tumors in mice. ( D ) Body weight change curve of mice in each group during the administration period. ( E ) Tumor volume change curves of mice in the four groups during the administration period. ( F ) Tumor weight of mice in the four groups. ( G ) Liver, spleen, and kidney indices of mice in the four groups. ( H ) Differences in liver MDA and SOD contents among the four groups of mice. ( I ) H&E staining of tumors, liver, spleen, and kidneys of mice in the four groups (200×). ( J ) IHC staining of LKB1, SIK2, SIK3, and PARD3 in tumor tissues from mice in the four groups (400×). ( K ) Protein expression of LKB1, SIK2, SIK3, and PARD3 in tumor tissues from mice in the four groups. ( L ) Expression of EMT marker proteins in tumor tissues from mice in the four groups. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the Vehicle control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the Erianin+5-FU group.

    Techniques Used: Staining, Immunohistochemistry, Expressing, Marker, Control

    Gene sequences (human).
    Figure Legend Snippet: Gene sequences (human).

    Techniques Used: Sequencing



    Similar Products

    pard3 (df3368)  (Affinity Biosciences)
    90
    Affinity Biosciences pard3 (df3368)
    Association of LKB1 with SIK1−3 and <t>PARD3</t> and their roles in GC. ( A ) The gene association network of LKB1 , SIK1 − 3 , and PARD3 was constructed using the GeneMANIA data portal. ( B ) Relationship between SIK2 expression and the survival curve of GC patients. ( C ) Relationship between SIK3 expression and the survival curve of GC patients. ( D ) The relationship between PARD3 and the survival curve of GC patients. ( E ) IHC staining of SIK2, SIK3, and PARD3 in paracancerous and GC tissues of GC patients (400×). ( F , G ) Differences in gene and protein expression levels of SIK2 , SIK3 , and PARD3 in paracancerous and GC tissues of GC patients ( n = 3). ( H , I ) Differential protein expression of LKB1, SIKs, and PARD3 in four GC cell lines and GES-1. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the normal group ( F ) or GES-1 group ( I ).
    Pard3 (Df3368), supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pard3+%28df3368%29/pmc11277420-227-20-27?v=Affinity+Biosciences
    Average 90 stars, based on 1 article reviews
    pard3 (df3368) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Association of LKB1 with SIK1−3 and PARD3 and their roles in GC. ( A ) The gene association network of LKB1 , SIK1 − 3 , and PARD3 was constructed using the GeneMANIA data portal. ( B ) Relationship between SIK2 expression and the survival curve of GC patients. ( C ) Relationship between SIK3 expression and the survival curve of GC patients. ( D ) The relationship between PARD3 and the survival curve of GC patients. ( E ) IHC staining of SIK2, SIK3, and PARD3 in paracancerous and GC tissues of GC patients (400×). ( F , G ) Differences in gene and protein expression levels of SIK2 , SIK3 , and PARD3 in paracancerous and GC tissues of GC patients ( n = 3). ( H , I ) Differential protein expression of LKB1, SIKs, and PARD3 in four GC cell lines and GES-1. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the normal group ( F ) or GES-1 group ( I ).

    Journal: International Journal of Molecular Sciences

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    doi: 10.3390/ijms25147973

    Figure Lengend Snippet: Association of LKB1 with SIK1−3 and PARD3 and their roles in GC. ( A ) The gene association network of LKB1 , SIK1 − 3 , and PARD3 was constructed using the GeneMANIA data portal. ( B ) Relationship between SIK2 expression and the survival curve of GC patients. ( C ) Relationship between SIK3 expression and the survival curve of GC patients. ( D ) The relationship between PARD3 and the survival curve of GC patients. ( E ) IHC staining of SIK2, SIK3, and PARD3 in paracancerous and GC tissues of GC patients (400×). ( F , G ) Differences in gene and protein expression levels of SIK2 , SIK3 , and PARD3 in paracancerous and GC tissues of GC patients ( n = 3). ( H , I ) Differential protein expression of LKB1, SIKs, and PARD3 in four GC cell lines and GES-1. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the normal group ( F ) or GES-1 group ( I ).

    Article Snippet: The following antibodies were obtained from various sources: β-actin (T0022), E-cadherin (AF0131), vimentin (AF7013), snail (AF6032), β-catenin (AF6266), LKB1 (AF6453), PARD3 (DF3368), and cleaved-caspase3 antibodies (AF7022) from Affinity Biosciences (Melbourne, Australia); Caspase3 (Cat. # 9662S), and PARP (Cat. # 9542S) antibodies from Cell Signaling Technology (Danvers, MA, USA); SIK2 (ab245211), and SIK3 (ab255701) antibodies from Abcam (Cambridge, UK); Twist (sc-6070) antibody from Santa Cruz Biotechnology (Dallas, CA, USA); And SIK1 (51045-1-AP) antibody from Proteintech (Chicago, IL, USA).

    Techniques: Construct, Expressing, Immunohistochemistry

    Erianin inhibits the expression of LKB1, SIK2/3 and PARD3, but not SIK1, in GC cells. ( A ) Molecular docking conformation of Erianin and LKB1 (PDB ID: 2WTK). Arrows indicated the locations of LKB1 and Erianin. The black box magnifies the 3D view of the docking cavity of Erianin and LKB1. ( B , C ) Distribution of amino acid residues around the binding pocket of Erianin and LKB1 and the chemical bonds formed. The oxygen atom on Erianin formed hydrogen bonds with Ser148, Ser199, Ser154, Thr147, Met150 and Thr98. The oxygen atom on Erianin formed a weak hydrogen bond with Ser199, and the carbon atom formed a weak hydrogen bond with Asp157. The carbon atom on the benzene ring of Erianin formed hydrophobic interactions with Leu202 and Ile75. The carbon atom on the C=C connecting the two benzene rings in Erianin formed a hydrophobic interaction with Phe415. ( D , E ) Erianin inhibited the fluorescence intensity of LKB1 in MGC803 and MKN45 cells (scale bar = 50 μm). ( F ) Effects of treating MGC803 cells with an Erianin concentration gradient on the expression of LKB1 , SIK1 − 3 , and PARD3 genes. ( G , H ) Effects of treating MGC803 cells with an Erianin concentration gradient on the expression of LKB1, SIK1−3, and PARD3 proteins. ( I ) Effects of treating MKN45 cells with an Erianin concentration gradient on the expression of LKB1 , SIK1 − 3 , and PARD3 genes. ( J , K ) Effects of treating MKN45 cells with an Erianin concentration gradient on the protein expression of LKB1, SIK1−3, and PARD3. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the control group.

    Journal: International Journal of Molecular Sciences

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    doi: 10.3390/ijms25147973

    Figure Lengend Snippet: Erianin inhibits the expression of LKB1, SIK2/3 and PARD3, but not SIK1, in GC cells. ( A ) Molecular docking conformation of Erianin and LKB1 (PDB ID: 2WTK). Arrows indicated the locations of LKB1 and Erianin. The black box magnifies the 3D view of the docking cavity of Erianin and LKB1. ( B , C ) Distribution of amino acid residues around the binding pocket of Erianin and LKB1 and the chemical bonds formed. The oxygen atom on Erianin formed hydrogen bonds with Ser148, Ser199, Ser154, Thr147, Met150 and Thr98. The oxygen atom on Erianin formed a weak hydrogen bond with Ser199, and the carbon atom formed a weak hydrogen bond with Asp157. The carbon atom on the benzene ring of Erianin formed hydrophobic interactions with Leu202 and Ile75. The carbon atom on the C=C connecting the two benzene rings in Erianin formed a hydrophobic interaction with Phe415. ( D , E ) Erianin inhibited the fluorescence intensity of LKB1 in MGC803 and MKN45 cells (scale bar = 50 μm). ( F ) Effects of treating MGC803 cells with an Erianin concentration gradient on the expression of LKB1 , SIK1 − 3 , and PARD3 genes. ( G , H ) Effects of treating MGC803 cells with an Erianin concentration gradient on the expression of LKB1, SIK1−3, and PARD3 proteins. ( I ) Effects of treating MKN45 cells with an Erianin concentration gradient on the expression of LKB1 , SIK1 − 3 , and PARD3 genes. ( J , K ) Effects of treating MKN45 cells with an Erianin concentration gradient on the protein expression of LKB1, SIK1−3, and PARD3. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the control group.

    Article Snippet: The following antibodies were obtained from various sources: β-actin (T0022), E-cadherin (AF0131), vimentin (AF7013), snail (AF6032), β-catenin (AF6266), LKB1 (AF6453), PARD3 (DF3368), and cleaved-caspase3 antibodies (AF7022) from Affinity Biosciences (Melbourne, Australia); Caspase3 (Cat. # 9662S), and PARP (Cat. # 9542S) antibodies from Cell Signaling Technology (Danvers, MA, USA); SIK2 (ab245211), and SIK3 (ab255701) antibodies from Abcam (Cambridge, UK); Twist (sc-6070) antibody from Santa Cruz Biotechnology (Dallas, CA, USA); And SIK1 (51045-1-AP) antibody from Proteintech (Chicago, IL, USA).

    Techniques: Expressing, Binding Assay, Fluorescence, Concentration Assay, Control

    Silencing the expression of LKB1, SIKs, and PARD3 and their interaction. ( A , B ) Effects of silencing LKB1 expression on the expression of SIK1−3 and PARD3 in GC cells. ( C , D ) Effects of silencing SIK2 expression on the expression of LKB1 and PARD3 in GC cells. ( E , F ) Effects of silencing SIK3 expression on the expression of LKB1 and PARD3 in GC cells. ( G , H ) Effects of silencing PARD3 expression on the expression of LKB1 and SIK1−3 in GC cells. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the NC group.

    Journal: International Journal of Molecular Sciences

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    doi: 10.3390/ijms25147973

    Figure Lengend Snippet: Silencing the expression of LKB1, SIKs, and PARD3 and their interaction. ( A , B ) Effects of silencing LKB1 expression on the expression of SIK1−3 and PARD3 in GC cells. ( C , D ) Effects of silencing SIK2 expression on the expression of LKB1 and PARD3 in GC cells. ( E , F ) Effects of silencing SIK3 expression on the expression of LKB1 and PARD3 in GC cells. ( G , H ) Effects of silencing PARD3 expression on the expression of LKB1 and SIK1−3 in GC cells. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the NC group.

    Article Snippet: The following antibodies were obtained from various sources: β-actin (T0022), E-cadherin (AF0131), vimentin (AF7013), snail (AF6032), β-catenin (AF6266), LKB1 (AF6453), PARD3 (DF3368), and cleaved-caspase3 antibodies (AF7022) from Affinity Biosciences (Melbourne, Australia); Caspase3 (Cat. # 9662S), and PARP (Cat. # 9542S) antibodies from Cell Signaling Technology (Danvers, MA, USA); SIK2 (ab245211), and SIK3 (ab255701) antibodies from Abcam (Cambridge, UK); Twist (sc-6070) antibody from Santa Cruz Biotechnology (Dallas, CA, USA); And SIK1 (51045-1-AP) antibody from Proteintech (Chicago, IL, USA).

    Techniques: Expressing

    Erianin inhibits tumor growth and the expression of LKB1, SIK2, SIK3, and PARD3 in the CDX mouse model. ( A ) Schematic diagram of the CDX model construction and drug administration treatment strategy. ( B ) Axillary tumor growth of mice in the five groups. ( C ) The size of isolated tumors from mice in the five groups. ( D ) Body weight changes of mice in the five groups during the administration period. ( E ) Changes in tumor volume during the administration of mice in the five groups. ( F ) Tumor mass in the five groups of mice. ( G ) Liver, spleen, and kidney index of mice in each group. ( H ) Differences in liver MDA and SOD levels of mice in the five groups. ( I ) Representative photomicrographs of pathological staining of tumors, liver, spleen, and kidney tissues of mice in the five groups (200×). ( J ) IHC staining results of LKB1, SIK2, SIK3, and PARD3 in mouse tumor tissues in the five groups (400×). ( K ) Changes in protein expression of LKB1, SIK2, SIK3, and PARD3 in tumor tissues of mice in the five groups. ( L ) Changes in the expression of EMT marker proteins in tumor tissues of mice in the five groups. ** p < 0.01 indicates statistical difference compared to the vehicle control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the 5-FU 50 mg/kg group.

    Journal: International Journal of Molecular Sciences

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    doi: 10.3390/ijms25147973

    Figure Lengend Snippet: Erianin inhibits tumor growth and the expression of LKB1, SIK2, SIK3, and PARD3 in the CDX mouse model. ( A ) Schematic diagram of the CDX model construction and drug administration treatment strategy. ( B ) Axillary tumor growth of mice in the five groups. ( C ) The size of isolated tumors from mice in the five groups. ( D ) Body weight changes of mice in the five groups during the administration period. ( E ) Changes in tumor volume during the administration of mice in the five groups. ( F ) Tumor mass in the five groups of mice. ( G ) Liver, spleen, and kidney index of mice in each group. ( H ) Differences in liver MDA and SOD levels of mice in the five groups. ( I ) Representative photomicrographs of pathological staining of tumors, liver, spleen, and kidney tissues of mice in the five groups (200×). ( J ) IHC staining results of LKB1, SIK2, SIK3, and PARD3 in mouse tumor tissues in the five groups (400×). ( K ) Changes in protein expression of LKB1, SIK2, SIK3, and PARD3 in tumor tissues of mice in the five groups. ( L ) Changes in the expression of EMT marker proteins in tumor tissues of mice in the five groups. ** p < 0.01 indicates statistical difference compared to the vehicle control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the 5-FU 50 mg/kg group.

    Article Snippet: The following antibodies were obtained from various sources: β-actin (T0022), E-cadherin (AF0131), vimentin (AF7013), snail (AF6032), β-catenin (AF6266), LKB1 (AF6453), PARD3 (DF3368), and cleaved-caspase3 antibodies (AF7022) from Affinity Biosciences (Melbourne, Australia); Caspase3 (Cat. # 9662S), and PARP (Cat. # 9542S) antibodies from Cell Signaling Technology (Danvers, MA, USA); SIK2 (ab245211), and SIK3 (ab255701) antibodies from Abcam (Cambridge, UK); Twist (sc-6070) antibody from Santa Cruz Biotechnology (Dallas, CA, USA); And SIK1 (51045-1-AP) antibody from Proteintech (Chicago, IL, USA).

    Techniques: Expressing, Isolation, Staining, Immunohistochemistry, Marker, Control

    5-FU inhibits the expression of LKB1, SIK2, SIK3, and PARD3 in GC cells. ( A ) CCK8 assay showing the inhibitory effect of different concentrations of 5-FU on MGC803 cells. ( B ) CCK8 detected the inhibitory effect of different concentrations of 5-FU on MKN45 cells. ( C , D ) 5-FU inhibited the protein expression of LKB1, SIK2, SIK3 and PARD3 in MGC803 cells in a dose-dependent manner. ( E , F ) 5-FU inhibited the proteins expression of LKB1, SIK2, SIK3 and PARD3 in MKN45 cells in a dose-dependent manner. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the control group.

    Journal: International Journal of Molecular Sciences

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    doi: 10.3390/ijms25147973

    Figure Lengend Snippet: 5-FU inhibits the expression of LKB1, SIK2, SIK3, and PARD3 in GC cells. ( A ) CCK8 assay showing the inhibitory effect of different concentrations of 5-FU on MGC803 cells. ( B ) CCK8 detected the inhibitory effect of different concentrations of 5-FU on MKN45 cells. ( C , D ) 5-FU inhibited the protein expression of LKB1, SIK2, SIK3 and PARD3 in MGC803 cells in a dose-dependent manner. ( E , F ) 5-FU inhibited the proteins expression of LKB1, SIK2, SIK3 and PARD3 in MKN45 cells in a dose-dependent manner. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the control group.

    Article Snippet: The following antibodies were obtained from various sources: β-actin (T0022), E-cadherin (AF0131), vimentin (AF7013), snail (AF6032), β-catenin (AF6266), LKB1 (AF6453), PARD3 (DF3368), and cleaved-caspase3 antibodies (AF7022) from Affinity Biosciences (Melbourne, Australia); Caspase3 (Cat. # 9662S), and PARP (Cat. # 9542S) antibodies from Cell Signaling Technology (Danvers, MA, USA); SIK2 (ab245211), and SIK3 (ab255701) antibodies from Abcam (Cambridge, UK); Twist (sc-6070) antibody from Santa Cruz Biotechnology (Dallas, CA, USA); And SIK1 (51045-1-AP) antibody from Proteintech (Chicago, IL, USA).

    Techniques: Expressing, CCK-8 Assay, Control

    5−FU combined with Erianin inhibits the expression of LKB1, SIK2/3, and PARD3 in GC cells and the migration and invasion ability of cells. ( A ) CCK8 examined the inhibitory effect of Erianin 25 nM or Erianin 50 nM combined with different concentrations of 5-FU on the cell viability of MGC803 or MKN45 cells. ( B ) Inhibitory effects of Erianin at 25 nM combined with 2.5 μg/mL 5-FU, and Erianin at 50 nM combined with 2.5 μg/mL 5-FU on the cell viability of MGC803 or MKN45. ( C ) Erianin at 25 nM combined with 5-FU at 2.5 μg/mL inhibited the fluorescent expression of LKB1 in MGC803 cells (scale bar = 50 μm). ( D ) 50 nM Erianin combined with 2.5 μg/mL 5-FU inhibited the fluorescent expression of LKB1 in MKN45 cells (scale bar = 50 μm). ( E ) Erianin combined with 5-FU inhibited the protein expression of LKB1, SIK1−3, and PARD3 in MGC803 cells. ( F ) Erianin combined with 5-FU inhibited the protein expression of LKB1, SIK1−3, and PARD3 in MKN45 cells. ( G ) Erianin combined with 5-FU inhibited the migration and invasion of MGC803 cells (scale bar = 100 μm). ( H ) Erianin combined with 5-FU inhibited the migration and invasion of MKN45 cells (scale bar =100 μm). ( I ) Erianin combined with 5-FU inhibited wound healing of MGC803 cells (scale bar = 100 μm). ( J ) Erianin combined with 5-FU inhibited wound healing of MKN45 cells (scale bar = 200 μm). * p < 0.05, ** p <0.01 indicates statistical difference compared to the control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the Erianin+5FU group.

    Journal: International Journal of Molecular Sciences

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    doi: 10.3390/ijms25147973

    Figure Lengend Snippet: 5−FU combined with Erianin inhibits the expression of LKB1, SIK2/3, and PARD3 in GC cells and the migration and invasion ability of cells. ( A ) CCK8 examined the inhibitory effect of Erianin 25 nM or Erianin 50 nM combined with different concentrations of 5-FU on the cell viability of MGC803 or MKN45 cells. ( B ) Inhibitory effects of Erianin at 25 nM combined with 2.5 μg/mL 5-FU, and Erianin at 50 nM combined with 2.5 μg/mL 5-FU on the cell viability of MGC803 or MKN45. ( C ) Erianin at 25 nM combined with 5-FU at 2.5 μg/mL inhibited the fluorescent expression of LKB1 in MGC803 cells (scale bar = 50 μm). ( D ) 50 nM Erianin combined with 2.5 μg/mL 5-FU inhibited the fluorescent expression of LKB1 in MKN45 cells (scale bar = 50 μm). ( E ) Erianin combined with 5-FU inhibited the protein expression of LKB1, SIK1−3, and PARD3 in MGC803 cells. ( F ) Erianin combined with 5-FU inhibited the protein expression of LKB1, SIK1−3, and PARD3 in MKN45 cells. ( G ) Erianin combined with 5-FU inhibited the migration and invasion of MGC803 cells (scale bar = 100 μm). ( H ) Erianin combined with 5-FU inhibited the migration and invasion of MKN45 cells (scale bar =100 μm). ( I ) Erianin combined with 5-FU inhibited wound healing of MGC803 cells (scale bar = 100 μm). ( J ) Erianin combined with 5-FU inhibited wound healing of MKN45 cells (scale bar = 200 μm). * p < 0.05, ** p <0.01 indicates statistical difference compared to the control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the Erianin+5FU group.

    Article Snippet: The following antibodies were obtained from various sources: β-actin (T0022), E-cadherin (AF0131), vimentin (AF7013), snail (AF6032), β-catenin (AF6266), LKB1 (AF6453), PARD3 (DF3368), and cleaved-caspase3 antibodies (AF7022) from Affinity Biosciences (Melbourne, Australia); Caspase3 (Cat. # 9662S), and PARP (Cat. # 9542S) antibodies from Cell Signaling Technology (Danvers, MA, USA); SIK2 (ab245211), and SIK3 (ab255701) antibodies from Abcam (Cambridge, UK); Twist (sc-6070) antibody from Santa Cruz Biotechnology (Dallas, CA, USA); And SIK1 (51045-1-AP) antibody from Proteintech (Chicago, IL, USA).

    Techniques: Expressing, Migration, Control

    Erianin combined with 5-FU inhibits tumor growth in CDX mouse model. ( A ) Schematic diagram of the CDX mouse model construction and the administration strategy for Erianin combined with 5-FU. ( B ) Growth of subcutaneous tumors in mice. ( C ) Photographs of subcutaneous tumors in mice. ( D ) Body weight change curve of mice in each group during the administration period. ( E ) Tumor volume change curves of mice in the four groups during the administration period. ( F ) Tumor weight of mice in the four groups. ( G ) Liver, spleen, and kidney indices of mice in the four groups. ( H ) Differences in liver MDA and SOD contents among the four groups of mice. ( I ) H&E staining of tumors, liver, spleen, and kidneys of mice in the four groups (200×). ( J ) IHC staining of LKB1, SIK2, SIK3, and PARD3 in tumor tissues from mice in the four groups (400×). ( K ) Protein expression of LKB1, SIK2, SIK3, and PARD3 in tumor tissues from mice in the four groups. ( L ) Expression of EMT marker proteins in tumor tissues from mice in the four groups. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the Vehicle control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the Erianin+5-FU group.

    Journal: International Journal of Molecular Sciences

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    doi: 10.3390/ijms25147973

    Figure Lengend Snippet: Erianin combined with 5-FU inhibits tumor growth in CDX mouse model. ( A ) Schematic diagram of the CDX mouse model construction and the administration strategy for Erianin combined with 5-FU. ( B ) Growth of subcutaneous tumors in mice. ( C ) Photographs of subcutaneous tumors in mice. ( D ) Body weight change curve of mice in each group during the administration period. ( E ) Tumor volume change curves of mice in the four groups during the administration period. ( F ) Tumor weight of mice in the four groups. ( G ) Liver, spleen, and kidney indices of mice in the four groups. ( H ) Differences in liver MDA and SOD contents among the four groups of mice. ( I ) H&E staining of tumors, liver, spleen, and kidneys of mice in the four groups (200×). ( J ) IHC staining of LKB1, SIK2, SIK3, and PARD3 in tumor tissues from mice in the four groups (400×). ( K ) Protein expression of LKB1, SIK2, SIK3, and PARD3 in tumor tissues from mice in the four groups. ( L ) Expression of EMT marker proteins in tumor tissues from mice in the four groups. * p < 0.05, ** p < 0.01 indicates statistical difference compared to the Vehicle control group. # p < 0.05, ## p < 0.01 indicates statistical difference compared to the Erianin+5-FU group.

    Article Snippet: The following antibodies were obtained from various sources: β-actin (T0022), E-cadherin (AF0131), vimentin (AF7013), snail (AF6032), β-catenin (AF6266), LKB1 (AF6453), PARD3 (DF3368), and cleaved-caspase3 antibodies (AF7022) from Affinity Biosciences (Melbourne, Australia); Caspase3 (Cat. # 9662S), and PARP (Cat. # 9542S) antibodies from Cell Signaling Technology (Danvers, MA, USA); SIK2 (ab245211), and SIK3 (ab255701) antibodies from Abcam (Cambridge, UK); Twist (sc-6070) antibody from Santa Cruz Biotechnology (Dallas, CA, USA); And SIK1 (51045-1-AP) antibody from Proteintech (Chicago, IL, USA).

    Techniques: Staining, Immunohistochemistry, Expressing, Marker, Control

    Gene sequences (human).

    Journal: International Journal of Molecular Sciences

    Article Title: Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway

    doi: 10.3390/ijms25147973

    Figure Lengend Snippet: Gene sequences (human).

    Article Snippet: The following antibodies were obtained from various sources: β-actin (T0022), E-cadherin (AF0131), vimentin (AF7013), snail (AF6032), β-catenin (AF6266), LKB1 (AF6453), PARD3 (DF3368), and cleaved-caspase3 antibodies (AF7022) from Affinity Biosciences (Melbourne, Australia); Caspase3 (Cat. # 9662S), and PARP (Cat. # 9542S) antibodies from Cell Signaling Technology (Danvers, MA, USA); SIK2 (ab245211), and SIK3 (ab255701) antibodies from Abcam (Cambridge, UK); Twist (sc-6070) antibody from Santa Cruz Biotechnology (Dallas, CA, USA); And SIK1 (51045-1-AP) antibody from Proteintech (Chicago, IL, USA).

    Techniques: Sequencing